The UK’s second-largest drugmaker, GSK, expects to hear by the end of August whether the US regulator will expand the label for Jemperli (dostarlimab). 25 April 2024
US biopharma Abeona Therapeutics was trading nearly 50% lower in Tuesday morning’s trading after announcing a regulatory update for prademagene zamikeracel (pz- 23 April 2024
Japanese pharma giant Takeda has picked up a new approval for subcutaneous Entyvio (vedolizumab), for maintenance therapy of severely active Crohn’s disease (CD 19 April 2024
The Icelandic-Israeli pairing of Alvotech and Teva Pharmaceutical Industries have announced that the US Food and Drug Administration (FDA) has approved Selarsdi 17 April 2024
The US Food and Drug Administration has given a green light to BrainStorm Cell Therapeutics (Nasdaq: BCLI) for the design of a Phase IIIb trial for NurOwn (MSC- 10 April 2024
The US regulator has for once again rebuffed efforts on the part of Supernus Pharmaceuticals (Nasdaq: SUPN) to register its Parkinson’s disease candidate SPN-83 9 April 2024
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.